复星医药：法莫替丁注射液药品注册申请获批

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, indicating a significant advancement in the company's product portfolio and potential market opportunities [1] Group 1: Product Approval - The drug, Famotidine Injection, is a self-developed chemical medication by the group [1] - The approved indication is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] - The approval highlights the company's commitment to addressing various causes of gastric and duodenal mucosal erosion and bleeding [1]